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The objective of this study was to evaluate and compare the 
safety, tolerability and immunogenicity for two seasonal influ-
enza subunit vaccines, one with MF59 adjuvant (Fluad®) and 
one without an adjuvant (Agrippal®).
A total of 195 subjects aged ≥ 65 years were enrolled to receive 
one dose of vaccine intramuscularly, 96 were vaccinated with 
Fluad®, 99 received Agrippal®.
Blood samples were taken from all subjects in order to assess their 
antibody titre by the haemagglutination inhibition assay (HI), before 
(Time 0) and after (Time 1: 28 ± 7 days) vaccination, against the 
A/H3N2 (A/Moscow/10/99), A/H1N1 (A/New Caledonia/20/99) and 
B/Shandong/7/97 antigens contained in the influenza vaccine in the 
2002/2003 influenza season for the northern emisphere.
A good humoral antibody response was detected for both vac-
cines, meeting all the criteria of EMEA. The number of subjects 
in whom a ≥ 4-fold increase in antibody titre was recorded, in 
comparison with the pre-vaccination value, proved to be lower 
in the group vaccinated with Agrippal® than in those vaccinated 
with the adjuvated preparation. Fluad® exhibited better immu-
nogenicity than Agrippal®. This difference was probably linked 
to the potentiated immune stimulation exerted by the adjuvant 
molecules.
These results take on a particular importance if we consider 
that the immune system is weaker in the elderly; the admin-
istration of an adjuvated vaccine in such subjects is clearly 
preferable in that it provides greater and more prolonged 
protection.
Both vaccines were generally well tolerated; no severe adverse 
events occurred in any of the subjects vaccinated, confirming the 
excellent safety profile of Fluad® and Agrippal®.
Introduction
although some molecules, such as zanamivir and osel-
tamivir, can be used to combat influenza viruses [1-5], 
it has long been recognized that vaccines are the most 
efficacious weapon against influenza. this conviction 
has guided experimental research since the virus was 
first isolated in 1933 [6].
today, the vaccines most frequently used in mass vac-
cination are “split” vaccines, “subunit” vaccines and 
“virosomal” vaccines. in elderly subjects these vac-
cines, administered intramuscularly (deltoid muscle), 
did not exhibit sufficient immunogenicity, so adjuvants 
as mF59® have been introduced [7].
until such time as different formulations become availa-
ble, molecules of a different nature (adjuvants) are used 
to improve the immunological response; when associ-
ated to specific antigens, these molecules are able to in-
duce a heightened immune response [8-10]. one of the 
best-known adjuvants currently used in italy is mF59® 
(novartis Vaccines and Diagnostics Srl, italy) [11], the 
safety, tolerability and immunogenicity of which have 
been the subject of numerous clinical and experimental 
studies [12-17].
the aim of the present study was to evaluate the im-
munogenicity of an mF59-adjuvated subunit influenza 
vaccine in comparison with that of a conventional subu-
nit vaccine. Furthermore we evaluated the safety and 
tolerability of both vaccines.
Materials and methods
the study was approved by the local ethics committee.
Study population
We enrolled 195 subjects aged ≥ 65 years, who were 
randomly selected from among residents in social com-
munity facilities during the 2002/2003 influenza season 
in messina (South italy).
all subjects were given clear, complete, written infor-
mation regarding the experimental treatment, in order to 
obtain a fully informed consent signed; whenever neces-
sary, explanations were also provided by medical staff. 
the study protocol conformed to the ethical guidelines 
of the 1975 Declaration of Helsinki and good clinical 
practice.
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using a computer generated list, subjects were rand-
omized to receive a mF59-adjuvated (Fluad®; n= 96), 
or a non-adjuvanted subunit influenza vaccine (agrip-
pal®; n = 99).
after thorough medical examination, blood samples 
were taken from all subjects in order to assess their an-
tibody titres, before (time 0) and after (time 1: 28 ± 7 
days) vaccination, against a and B antigens contained in 
the influenza vaccine in the 2002/2003 season.
VaccineS
each subject received a single 0.5mL intramuscular 
dose of the assigned vaccine, preferably into the deltoid 
region.
Both vaccines contained the surface antigens of the 
strains indicated by the World Health organization 
(WHo) for the northern hemisphere (nH) during the 
2002/03 influenza season:
• a/H3n2 (a/moscow/10/99);
• a/n1n1 (a/new caledonia/20/99);
• B/Shandong/7/97.
the adjuvated vaccine (Fluad®) was formulated as fol-
lows: 15 μg of each of the surface antigens, obtained 
from virions cultivated in egg and adjuvated with 
mF59c.1. the mF59c.1 adjuvant is composed of 9.75 
mg of squalene; 1.175 mg of polysorbate 80; 1.175 mg 
of sorbitan trioleate; 0.66 mg of sodium citrate; 0.04 mg 
of citric acid and water for injectable preparations.
the non-adjuvated vaccine (agrippal®) was made up of 
15 μg of each of the surface antigens, obtained from vir-
ions cultivated in egg and inactivated in formaldehyde 
and suspended in a solution of sodium chloride, potas-
sium chloride, monobasic potassium phosphate, bi-hy-
drated bibasic sodium phosphate, magnesium chloride, 
calcium chloride and water for injectable preparations.
immunogenicity
in order to assess the short-term immunogenic and 
protective efficacy of the two types of vaccine, blood 
samples were taken from all patients 28 ± 7 days after 
vaccination.
the laboratory tests recommended by the european 
medicine agency (emea) to assess immunogenic ef-
ficacy are haemagglutination inhibition (Hi) and single 
radial haemolysis (SRH).
our laboratory carried out the Hi test according to the 
method of couch [18]. When the Hi test is used, the 
criteria for evaluating vaccine immunogenicity in sub-
jects above the age of 60 years, as established by the 
committee for Proprietary medicinal Products (cPmP/
BWP/214/96), are the following: 
• a number of seroconversions (pre-vaccination ti-
tre < 1:10, post-vaccination titre ≥ 1:40) or a signifi-
cant increase in the antibody titre (equal to or greater 
than 4 times the initial value) in more than 30% of 
the subjects vaccinated;
• the increase in antibody titre, expressed as the geo-
metric mean (Geometric mean titre Gmt), must be 
at least doubled;
• the percentage of subjects with an antibody ti-
tre ≥ 1:40 must be greater than 60%.
thus, for each viral antigen, we calculated the Geomet-
ric mean titre (Gmt) of the sera pre- and post-vac-
cination and the ratio of the Gmt (GmR – Geometric 
mean Ratio).
Tab. I. Demographic features of the subjects enrolled in the 
groups vaccinated with AGRIPPAL® and FLUAD®.
Demographic
variable
AGRIPPAL® FLUAD®
Females 74 70
Males 25 26
Mean age (years) ± SD 80.29 ± 7.78 79.04 ± 8.29
Tab. II. Numbers and percentages of subjects meeting the EMEA (CPMP/BWP/214/96) criteria. 
A/H3N2
(A/MOSCOW/10/99)
A/H1N1
(A/NEW CALEDONIA/20/99)
B
(B/SHANDONG/7/97)
Vaccine AGRIPPAL® FLUAD® AGRIPPAL® FLUAD® AGRIPPAL® FLUAD®
Protected before vaccination 83
84%
74
77%
70
70.7%
70
72.9%
67
67.6%
73
76%
Protected 
after vaccination
98
98.9%
95
98.9%
95
96%
92
95.8%
97
98%
93
96.6%
Sera-Conversions 1
1%
4
4.2%
10
9.9%
4
4.2%
2
2%
11
11.5%
≥ 4 titre upgrade
conversions included
41
41.4%
59
61.4%
42
42.4%
53
55.2%
45
45.4%
67
69.7%
GMT
T0 92.02 80 58.38 65.35 49.35 30.40
GMT
T1 256.98 377.81 185.34 255.82 170.41 160
GMR
T1/T0 2.76 4.72 3.17 3.91 3.45 5.26
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Safety and tolerability
We assessed any adverse reactions, both at the injection 
site and at the systemic level and any Serious adverse 
event (Sae) reported during the trial; the time course 
and intensity of expression were considered. observa-
tion for solicited local and system reactions was contin-
ued for 7 days after vaccination using a clinical diary. 
Sae were monitored by the investigators for 1 month.
StatiStical analySeS
Immunogenicity 
Statistical analysis of the data was performed by calculat-
ing the Gmt, with a confidence interval of 95% (95% ci), 
and the GmR, by means of excel (microsoft) software.
Safety and tolerability
the χ2 test was applied by means of the PePi 4.0 soft-
ware (J.H. abramson e P.m. Gahlinger, Sagenbrush, 
London, UK); a value of p ≤ 0.05 was taken to be statis-
tically significant.
Results
table i shows the main demographic features of the 
subjects enrolled in the study. no significant differences 
were recorded between the two study groups.
Fig. 1. GMT and 95% CI values observed in the non-adjuvated 
vaccine group at times T0 and T1.
Fig. 2. GMT and 95% CI values observed in the adjuvated vaccine 
group at times T0 and T1.
Fig. 3. GMT and 95% CI values observed for the single viruses at 
times T0 and T1 in both study groups.
Fig. 4. GMR values observed at times T0 and T1 in both study 
groups.
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immunogenicity
Before vaccination, no significant difference was re-
corded between the two study groups in terms of the 
number of subjects who displayed protective levels 
with regard to the three vaccine strains considered (a/
moscow/10/99, p = 0.3126; a/new caledonia/20/99, 
p = 0.8543; B Shandong/7/97, p = 0.2549).
in the subjects vaccinated with agrippal®, we observed 
an increase in antibody titre (≥ 4 times the initial value) 
in 40 subjects (40.4%, ic 95% 30.7-50.1) with regard 
to a/moscow/10/99, in 32 (32.3%, ic 95% 23.1-41.5) 
for a/new caledonia/20/99 and in 43 (43.4%, ic 95% 
33.6-53.1) for B Shandong/7/97 (tab. ii). in the group 
vaccinated with Fluad®, an increase in antibody titre 
was recorded in 55 subjects (57.3%, ic 95% 47.4-67.2) 
for a/moscow/10/99, in 49 (51%, ic 95% 40.9-61.0) 
for a/new caledonia/20/99 and in 56 (58.3%, ic 95% 
48.4-68.1) for B Shandong/7/97 (tab. ii).
Seroconversion after administration of the non-adju-
vated vaccine (agrippal®) was recorded in 1 subject 
Fig. 5. Number of subjects with lo-
cal and/or systemic reactions after 
administration of Agrippal® (Fig. 5a) 
and Fluad® (Fig. 5b).
5a
5b
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(1%, ic 95% 0-2.96) for a/moscow/10/99, in 10 
(10.1%, ic 95% 4.1-16.1) for a/new caledonia/20/99 
and in 2 (2.2%, ic 95% 0-5.1) for B Shandong/7/97. 
in the subjects vaccinated with the adjuvated vaccine 
(Fluad®) seroconversion occurred in 4 subjects (4.2%, 
ic 95% 0.2-8.2) for a/moscow/10/99, in 4 (4.2%, 
ic 95% 0.2-8.2) for a/new caledonia/20/99 and in 
11 (11.5%, ic 95% 5.1-17.8) for B Shandong/7/97 
(tab. ii).
in the non-adjuvated vaccine group, administration of 
the vaccine increased the number of protected subjects 
as follows: for the virus a/moscow/10/99 from 83 
(84%, ic 95% 76.7-91.22) to 98 (98.9%, ic 95% 96.84-
100); for a/new caledonia/20/99 from 70 (70.7%, ic 
95% 61.73-79.6) to 95 (96%, ic 95% 92,13-99,86); and 
for B/Shandong/7/97 from 67 (67.6%, ic 95% 57.73-
76.26) to 97 (98%, ic 95% 95,2-100).
in the group vaccinated with the adjuvated vaccine, 
administration increased the number of protected sub-
jects as follows: for the virus a/moscow/10/99 from 74 
(77%, ic 95% 68.6-85.4) to 95 (98.9%, ic 95% 96.8-
100); for a/new caledonia/20/99 from 70 (72.9%, ic 
95% 64.00-81.8) to 92 (95.8%, ic 95% 96.8-100); and 
for B/Shandong/7/97 from 73 (76%, ic 95% 67.4-84.5) 
to 93 (96.8%, ic 95% 93.2-100).
Figure 1 shows the Gmt values observed before and 
after vaccination in the subjects who received the non-
adjuvated vaccine, together with the 95% ci values.
Figure 2 shows the Gmt values observed before 
and after vaccination in the subjects who received 
the adjuvated vaccine, together with the 95% ci 
values.
Figure 3 shows the Gmt values observed for the single 
virus at times t0 and t1 in the 2 study groups. as will 
be seen, the Gmt values recorded in the subjects vac-
cinated with Fluad® proved to be higher.
at 3 weeks post-vaccination, significantly higher Gmts 
were reported for both vaccine groups versus baseline as 
ic show (Figs. 1 and 2). in the Fluad® group post-vac-
cination Gmts against both a strains were significantly 
higher compared with the agrippal® group (a/H1n1: 
255.82 versus 185.34 respectively; a/H3n2: 377.81 
versus 256.98, respectively). against the B strain post-
vaccination Hi titers were 170.41 in the agrippal® group 
and 160 in the Fluad®group.
the ratios between the Gmt values observed before 
and after vaccination in both study groups are shown in 
Figure 4.
Safety and tolerability
During the entire clinical follow-up, no serious Sae 
were reported.
Figures 5a and 5b show the solicited local and systemic 
reactions recorded after administration of both types of 
vaccine. Following the administration of the non-adju-
vated vaccine, 27 subjects (27.27%, ic 95% 18.5-36.1) 
suffered at least one solicited reactions at the injection 
site (pain on touching, swelling, erythema). in the same 
group, 18 subjects (18.2%, ic 95% 10.6-25.8) had sys-
temic symptoms; in particular, 2 subjects had all of the 
systemic manifestations (Figure 5a).
in the group vaccinated with Fluad®, 48 of the 96 
subjects (50%, ic 95% 39.9-60.0) reported at least 
one solicited reactions at the injection site and 15 had 
all of the local symptoms (Figure 5b). With regard to 
solicited systemic symptoms, 23 subjects (23.96%, 
ic 95% 15.4-32.5) had signs and/or symptoms; in 
particular, 2 suffered all of the systemic symptoms 
(Figure 5b). Statistical analysis by means of the χ2 
test revealed a significant difference between the two 
groups with regard to both general and local symp-
toms (p < 0.001). Reactions reported in both vaccine 
groups were generally of mild or moderate intensity 
and short living.
on analysing the concomitance of systemic and local 
symptoms, it emerged that 7 of the subjects who re-
ceived the non-adjuvanted vaccine presented only local 
symptoms; none had systemic symptoms alone, and 20 
suffered both systemic and local symptoms (Figure 6). 
in the group of subjects who received the adjuvanted 
vaccine, 16 presented local symptoms alone, 5 had only 
systemic signs/symptoms, and 32 suffered both sys-
temic and local symptoms (Figure 6). When applied to 
these data, the χ2 test revealed a significant difference 
between the two groups (p < 0.001).
Discussion
the results of this study provide a further contribution to 
the assessment of the immunogenicity of the mF59-adju-
vanted influenza vaccine (Fluad®) in comparison with the 
conventional non-adjuvanted vaccine (agrippal®).
although the high number of subjects with seroprotec-
tive titrers already at baseline in both vaccine groups, 
the number of subjects in whom a ≥ 4-fold increase 
in antibody titre was recorded, in comparison with the 
pre-vaccination value, was lower in the group vacci-
nated with agrippal® than in those vaccinated with the 
Fluad®. moreover, the GmR values were higher in the 
Fig. 6. Number of subjects with local and systemic reactions af-
ter administration of each vaccine (with or without adjuvant).
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group that received the adjuvanted than in the group 
that received the non-adjuvanted vaccine. these results 
take on a particular importance if we consider that the 
immune system is weaker in the elderly. therefore, the 
administration of an adjuvanted vaccine in such subjects 
is clearly preferable in that it provides greater and more 
prolonged protection.
no serious adverse events occurred in any of the 
subjects vaccinated, confirming the excellent safety 
profile.
as reported in previous publications [15, 19-22], Fluad® 
induced more solicited local and systemic reactions than 
agrippal®. Reactions were usually of mild or moderate 
intensity and transient and did not require any medical 
intervention.
Conclusions
the higher immunogenicity of Fluad® in this trial ena-
bles us to conclude that the adjuvanted vaccine Fluad® 
is preferable to non-adjuvated formulations in anti-in-
fluenza strategies aimed at the elderly.
the greater antibody expression observed after the 
administration of the adjuvanted vaccine means that 
elderly subjects, whose immune reactivity may be com-
promised, will not be left with an insufficient antibody 
titre for part of the influenza season.
in agreement with the data reported in the national and 
international literature [15, 19-22], our results show that 
both local and systemic reactions are negligible in terms 
of intensity and duration.
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